RxDoctor Payments DataLook up a doctor →

Alvaro Murcia, MD

Cardiovascular Disease · Pembroke Pines, FLNPI 1104822261

Payments from drug & device makers

$4,000,475in general payments, 2019–2025

Across 354 payments — averaging $11,301 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.6M
  • Novartis$627K
  • BD$314K
  • AbbVie$199K
  • AstraZeneca$110K
  • Johnson & Johnson$65K
  • plus $61K from 16 others

What the payments were for

  • Food & beverage$1,72598%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,000,475 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$124,562
Medicare patients
437
Services billed
1,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$170,556
XareltoRivaroxaban52$64,186
FarxigaDapagliflozin Propanediol44$49,745
EntrestoSacubitril/Valsartan31$47,658
Repatha SureclickEvolocumab28$28,677
VascepaIcosapent Ethyl38$24,929
Repatha SyringeEvolocumab35$20,233
JardianceEmpagliflozin16$18,157
LivaloPitavastatin Calcium15$12,910
BrilintaTicagrelor16$9,513
Praluent PenAlirocumab11$6,415
Ezetimibe155$4,100
Rosuvastatin Calcium336$3,389
Atorvastatin Calcium306$2,654
Metoprolol Succinate144$1,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,624,632$170,556142 claims
Johnson & JohnsonXarelto$65,169$64,18652 claims
AstraZenecaFarxiga, Brilinta$109,705$59,25860 claims
NovartisEntresto$627,432$47,65831 claims
Boehringer IngelheimJardiance$172$18,15716 claims
Kowa Pharmaceuticals America, Inc.Livalo$18$12,91015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →